Earn AMA PRA Category 1 Credit™
Setting a Course Toward Prostate Cancer Prevention: Communicating the Evidence to Our Patients
An On-Demand Webinar
Estimated time to complete: 45 minutes
CME Activity Release Date: August 27, 2009
CME Activity Expired: August 26, 2010. CME credit no longer available
Needs Statement and Target Audience
This activity is designed to provide educational information related to current guidelines on screening for prostate cancer and is intended for urologists and other health care professionals who manage this disease state.
Expert Lecture Delivered By:
Louis Kuritzky, MD Click here for biography >>
Assistant Professor
Department of Community Health and Family Medicine
University of Florida
Gainesville, Florida
Additional Expert Faculty Contributing to Content Development:
David M. Albala, MD, FACS Click here for biography >>
Activity Medical Director
Professor of Urology
Director, Center for Minimally Invasive Urologic Surgery
Duke University Medical Center
Durham, North Carolina
Martin M. Miner, MD Click here for biography >>
Clinical Associate Professor
Warren Alpert Medical School of Brown University
Providence, Rhode Island
Learning Objectives
- At the conclusion of this activity, participants should be able to:
- Discuss the rationale and appropriate use of clinical guidelines in screening for prostate cancer.
- Describe individualized patient risk factors for prostate cancer and how to incorporate this information into an overall assessment and counseling strategy with patients.
- Recognize the differences, strengths, and limitations of current prostate cancer screening tests.
- Demonstrate familiarity with current evidence assessing prostate cancer prevention strategies, including chemoprevention with pharmacologic agents.
 |
 |
Co-sponsored by the Duke University School of Medicine and The France Foundation
CLICK HERE TO VIEW TECHNICAL REQUIREMENTS
Commercial Support Acknowledgment
This educational activity is supported by an educational grant from GlaxoSmithKline.
Unapproved Use Disclosure
The Duke University School of Medicine requires CME faculty (speakers) to disclose to the attendees when products or procedures being discussed are off-label, unlabeled, experimental, and/or investigational (not FDA approved); and any limitations on the information that is presented, such as data that are preliminary or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of U.S. Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. If you have questions, contact the medical affairs department of the manufacturer for the most recent prescribing information.
Staff and Content Validation Reviewer Disclosure
The staff involved with this activity and any content validation reviewers of this activity have reported no relevant financial relationships with commercial interests.
Resolution of Conflicts of Interest
In accordance with the ACCME Standards for Commercial Support of CME, the Duke University School of Medicine will implement mechanisms, prior to the planning and implementation of this CME activity, to identify and resolve conflicts of interest for all individuals in a position to control content of this CME activity.
Planning Committee and Faculty Disclosure
The following speakers and/or planning committee members have indicated they have no relationships with industry to disclose relative to the content of this CME activity:
- Theodore Bruno, MD
- Wendy Scales, PhD
- Heather Tarbox, MPH
The following speakers and/or planning committee members have indicated that they have relationships with industry to disclose:
- David M. Albala, MD, FACS, fulfills the role of speaker for GlaxoSmithKline, Applied Medical, Boehringer Ingelheim, and sanofi-aventis.
- Louis Kuritzky, MD, fulfills the role of Advisory Board member for Eli Lilly/sanofi-aventis, sanofi-aventis, and Takeda. He fulfills the role of Speaker for Eli Lilly/sanofi-aventis, Novartis-NovoNordisk, sanofi-aventis, and Takeda. He fulfills the role of Consultant for Novartis-NovoNordisk and is an Independent Contractor for Amylin.
- Martin M. Miner, MD, fulfills the role of Principal Investigator for GlaxoSmithKline and is a consultant for sanofi-aventis.
Disclaimer
The information provided in this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a health care provider relative to diagnostic and treatment options of a specific patient's medical condition.
Accreditation
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the Duke University School of Medicine and The France Foundation. The Duke University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation
The Duke University School of Medicine designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
How to Receive Credit - CME Activity Expired